Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934208 | 0.95 | SLC5A7 (0.54) | SLC5A7KMT2AMEN1HRH1HSD17B10 | |
| SCHEMBL4930039 | 0.87 | MAPK14 (0.58) | SLC5A7KMT2AMEN1HSD17B10MMP13 | |
| SCHEMBL4666647 | 0.87 | SLC5A7 (0.54) | SLC5A7KMT2AMEN1HSD17B10TDP1 | |
| SCHEMBL4933296 | 0.86 | SLC5A7 (0.60) | SLC5A7KMT2AMEN1OPRK1PABPC1 | |
| SCHEMBL4933614 | 0.84 | LMNA (0.53) | SLC5A7KMT2AMEN1HSD17B10TDP1 | |
| SCHEMBL14026961 | 0.84 | SLC5A7 (0.54) | SLC5A7KMT2AMEN1HSD17B10MMP13 | |
| SCHEMBL4795029 | 0.83 | SCN1A (0.58) | SLC5A7KMT2AMEN1HRH1OPRK1 | |
| SCHEMBL14026963 | 0.83 | LMNA (0.64) | SLC5A7KMT2AMEN1PABPC1MMP13 | |
| Hydrochloric Acid SCHEMBL4664680 | 0.83 | SLC5A7 (0.53) | SLC5A7KMT2AMEN1MMP13TDP1 | |
| SCHEMBL4664201 | 0.82 | MMP13 (0.55) | SLC5A7KMT2AMMP13NPC1APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | SLC5A7 4671/4885KMT2A 3029/4885MEN1 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.